Biotage AB and McMaster University sign joint agreement to develop new chemistry platform
"This partnership brings together cutting edge synthesis and purification tools with radiopharmaceutical research which spans basic science to the development and testing of novel imaging and therapy agents. The new platform technologies will facilitate the process of producing tracers and therapeutics and it will be particularly useful for developing radiolabeled analogues of new drug candidates. The latter aim is particularly important as imaging is playing an increasingly important role in early clinical trials," Dr. John F. Valliant, Associate Professor of Chemistry and Medical Physics, and Acting Director of McIARS stated.
Most read news
Topics
Organizations
Other news from the department science
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.